Chronic eosinophilic leukemia with the FIP1L1-PDGFRα fusion gene in a patient with a history of combination chemotherapy

International Journal of Hematology

Volumn 83, Issue 2, 2006, Pages 152-155

  Tanaka, Yasuhiro ^a   Kurata, Masayuki ^a   Togami, Katsuhiro ^a   Fujita, Haruyuki ^a   Watanabe, Naoko ^a,c   Matsushita, Akiko ^a   Maeda, Akinori ^a   Nagai, Kenichi ^a   Sada, Akiko ^b   Matsui, Toshimitsu ^b   Takahashi, Takayuki ^a  

^a KOBE CITY MEDICAL CENTER GENERAL HOSPITAL   (Japan)

^b KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c UNIVERSITY OF TOKYO   (Japan)

Author keywords

Chronic eosinophilic leukemia; FIP1L1 PDGFR fusion gene; Hypereosinophilic syndrome; Imatinib mesylate; Secondary leukemia

Indexed keywords

BLEOMYCIN; CYCLOPHOSPHAMIDE; DNA; DOXORUBICIN; GENE PRODUCT; HYBRID PROTEIN; IMATINIB; METHOTREXATE; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PREDNISOLONE; PROTEIN FIP1 LIKE 1; UNCLASSIFIED DRUG; VINCRISTINE; ANTINEOPLASTIC AGENT; CLEAVAGE AND POLYADENYLATION SPECIFICITY FACTOR; FIP1L1 PDGFRA FUSION PROTEIN, HUMAN; FIP1L1-PDGFRA FUSION PROTEIN, HUMAN; ONCOPROTEIN; PIPERAZINE DERIVATIVE; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PYRIMIDINE DERIVATIVE;

ADULT; ANEMIA; ARTICLE; BONE MARROW CELL; CANCER COMBINATION CHEMOTHERAPY; CASE REPORT; CHROMOSOME 4Q; CHROMOSOME ANALYSIS; CHROMOSOME DELETION 4; DNA SEQUENCE; EOSINOPHILIA; EOSINOPHILIC LEUKEMIA; EXON; FEVER; FUSION GENE; HEMATOPOIETIC CELL; HUMAN; HYPEREOSINOPHILIC SYNDROME; KARYOTYPE; MALE; NONHODGKIN LYMPHOMA; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; THROMBOCYTOPENIA; CHEMICALLY INDUCED DISORDER; CHRONIC DISEASE; GENETICS; MOLECULAR GENETICS;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHRONIC DISEASE; HUMANS; HYPEREOSINOPHILIC SYNDROME; LYMPHOMA, NON-HODGKIN; MALE; MOLECULAR SEQUENCE DATA; MRNA CLEAVAGE AND POLYADENYLATION FACTORS; ONCOGENE PROTEINS, FUSION; PIPERAZINES; PYRIMIDINES; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR ALPHA; SEQUENCE ANALYSIS, DNA;

EID: 33646840877     PISSN: 09255710     EISSN: None     Source Type: Journal    
DOI: 10.1532/IJH97.05048     Document Type: Article

References (26)

1. Chusid MJ, Dale DC, West BC, et al. The hypereosinophilic syndrome: analysis of fourteen cases with review of the literature. Medicine. 1975;54:1-27.
2. Bain BJ. Eosinophilic leukemias and the idiopathic hypereosinophilic syndrome. Br J Haematol. 1996;95:2-9.
3. Bain BJ. Cytogenetic and molecular genetic aspects of eosinophilic leukemias. Br J Haematol. 2003;122:173-179.
4. Schaller JL, Burkland GA. Case report: rapid and complete control of idiopathic hypereosinophilia with imatinib mesylate. MedGenMed. 2001;3:9.
5. Gleich GJ, Leiferman KM, Pardanani A, Tefferi A, Butterfield JH. Treatment of hypereosinophilic syndrome with imatinib mesylate. Lancet. 2002;359:1577-1578.
6. Tan D, Hwang W, Hg HJ, Goh YT, Tan P. Successful treatment of idiopathic hypereosinophilic syndrome with imatinib mesylate: a case report. Int J Hematol. 2004;80:75-77.
7. Pardanani A, Reeder T, Porrata LF, et al. Imatinib therapy for hypereosinophilic syndrome and other eosinophilic disorders. Blood. 2003;101:3391-3397.
8. Frickhofen N, Marker-Hermann E, Reiter A, et al. Complete molecular remission of chronic eosinophilic leukemia complicated by CNS disease after targeted therapy with imatinib. Ann Hematol. 2004;83:477-480.
9. Salem Z, Zalloua PA, Chehal A, et al. Effective treatment of hypereosinophilic syndrome with imatinib mesylate. Hematol J. 2003;4:410-412.
10. Ault P, Cortes J, Koller C, Kaled ES, Kantarjian H. Response of idiopathic hypereosinophilic syndrome to treatment with imatinib mesylate. Leuk Res. 2002;26:881-884.
11. Cortes J, Ault P, Koller C, et al. Efficacy of imatinib mesylate in the treatment of idiopathic hypereosinophilic syndrome. Blood. 2003;101:4714-4716.
12. Cools J, DeAngelo DJ, Gotlib J, et al. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med. 2003;348:1201-1214.
13. Vandenberghe P, Wlodarska I, Michaux L, et al. Clinical and molecular features of FIP1L1-PDGFRA (+) chronic eosinophilic leukemia. Leukemia. 2004;18:734-742.
14. Smith KJ, Jacobson E, Hamza S, Skelton H. Unexplained hypereosinophilia and the need for cytogenetic and molecular genetic analysis. Arch Dermatol. 2004;140:584-588.
15. Ishii Y, Ito Y, Kuriyama Y, Tauchi T, Ohyashiki K. Successful treatment with imatinib mesylate of hypereosinophilic syndrome (chronic eosinophilic leukemia) with myelofibrosis. Leuk Res. 2004;28(suppl 1):S79-S80.
16. Klion AD, Robyn J, Akin C, et al. Molecular remission and reversal of myelofibrosis in response to imatinib mesylate treatment in patients with myeloproliferative variant of hypereosinophilic syndrome. Blood. 2004;103:473-478.
17. Klion A, Noel P, Aikin C, et al. Elevated serum tryptase levels identify a subset of patients with a myeloproliferative variant of idiopathic hypereosinophilic syndrome associated with tissue fibrosis, poor prognosis, and imatinib responsiveness. Blood. 2003;101:4660-4666.
18. Martinelli G, Malagola M, Ottaviani E, Rosti G, Trabacchi E, Baccarani M. Imatinib mesylate can induce complete molecular remission in FIP1L1-PDGFR-α positive idiopathic hypereosinophilic syndrome. Haematologica. 2004;89:236-237.
19. Harris NL, Jaffe ES, Diebold J, et al. World Health Organization classification of neoplastic disease of the hematopoietic and lymphoid tissues: report of the clinical advisory committee meeting - Airlie House, Virginia, November 1997. J Clin Oncol. 1999;17:3835-3849.
20. Brugnoni BD, Airo P, Rossi G, et al. A case of hypereosinophilic syndrome is associated with the expansion of a CD3-CD4+ T-cell population able to secrete large amounts of interleukin-5. Blood. 1996;87:1416-1422.
21. Cogan E, Schandene L, Crusiaux A, Cochaux P, Velu T, Goldman M. Clonal proliferation of type 2 helper T cells in a man with the hypereosinophilic syndrome. N Engl J Med. 1994;330:535-538.
22. Cools J, Stover EH, Wlodarska I, Marynen P, Gilliland DG. The FIP1L1-PDGFRα kinase in hypereosinophilic syndrome and chronic eosinophilic leukemia. Curr Opin Hematol. 2004;11:51-57.
23. Apperley JF, Gardembas M, Melo JV, et al. Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta. N Engl J Med. 2002;347:481-487.
24. Aguiar RT. Therapy-related chronic myeloid leukemia: an epidemiological, clinical and pathogenetic appraisal. Leuk Lymphoma. 1998;29:17-26.
25. Le Beau MM, Albain KS, Larson RA, et al. Clinical and cytogenetic correlations in 63 patients with therapy-related myelodysplastic syndromes acute nonlymphocytic leukemia: further evidence for characteristic abnormalities of chromosomes no. 5 and 7. J Clin Oncol. 1986;4:325-345.
26. Whang-Peng BJ, Young RC, Lee EC, et al. Cytogenetic studies in patients with secondary leukemia/dysmyelopoietic syndrome after different therapy modalities. Blood. 1988;71:403-414.